SCHEDULE 13G/A: Venrock Healthcare Funds Maintain Significant Stake in Applied Therapeutics, Disclosing 9.9% Beneficial Ownership

A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of Applied Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
• The filing pertains to their beneficial ownership of Common Stock of Applied Therapeutics, Inc. (CUSIP: 03828A101).
• As of December 31, 2024, the Reporting Persons collectively beneficially own 11,805,301 shares of Applied Therapeutics, Inc. Common Stock.
• This aggregate amount represents 9.9% of the Issuer's class of securities, rounded down from 9.99% due to EDGAR filing system limitations.
• The ownership includes both existing Common Stock and Pre-Funded Warrants exercisable into Common Stock.
• A 'Beneficial Ownership Blocker' provision in the Pre-Funded Warrants prevents exercise if it would result in the Reporting Persons owning more than 9.99% of the Issuer's outstanding Common Stock.
• The beneficial ownership percentage is calculated based on 116,356,474 shares of Common Stock outstanding as of November 6, 2024, plus 1,814,710 shares issuable upon exercise of the Pre-Funded Warrants.
• The Reporting Persons explicitly state that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual, legally mandated disclosure of beneficial ownership and does not contain information that would inherently suggest positive or negative sentiment. It is neutral in tone and content.

Risks

• The 'Beneficial Ownership Blocker' in the Pre-Funded Warrants limits the ability of the Reporting Persons to fully exercise their warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding Common Stock, potentially restricting their upside participation if the stock price increases significantly.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of significant ownership by institutional investors in a publicly traded biotechnology company. It reflects a continued investment by Venrock Healthcare Capital Partners in Applied Therapeutics, Inc., a common practice for venture capital or private equity firms that invest in healthcare and life sciences companies.

Related Party Transactions

• The Reporting Persons are members of a group for the purposes of this Schedule 13G, indicating a coordinated ownership and filing strategy among the Venrock Healthcare Capital Partners entities and their key personnel (Nimish Shah and Bong Koh).

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming their continued holding and adherence to ownership limits.
• Management: Informs management of the continued significant ownership by a key investor group, which may influence strategic discussions, though the filing explicitly states no intent to change or influence control.

Key Dates

Keywords

Applied Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G/A, Beneficial Ownership, Common Stock, Pre-Funded Warrants, SEC Filing, Institutional Investor, Biotechnology, Healthcare Investment